Insights

Type

Select all that apply

Topic

Select all that apply

icons/content-types/article article

For many who are new to drug development, the greatest challenge is not necessarily discovering a blockbuster molecule—it’s finding a team capable of carrying that molecule through the complexities that lie between the research lab and the patien...

icons/content-types/video webinar

Presented by Brian Haney, Ph.D., Director of Technical Operations, Curia Iain MacGilp, Ph.D., Director, GMP Production, Curia Listen in as our experts discuss: The basics of handling HPAPI's safely in GMP production settings The trad...

icons/content-types/white paper white paper

The COVID-19 pandemic has brought the global interdependency of pharmaceutical supply chains into sharp focus, exposing weak links and re-igniting discussions around the value of reshoring production. The U.S. Food and Drug Administration (FDA) repor...

icons/content-types/video webinar

Presenters: Ankit Agrawal, Senior Director, Commercial Strategy, Curia Anish Parikh, Vice President, Drug Product Sales & Marketing, Curia Listen in as our experts discuss: The shortage of sterile manufacturing capacity within CDMOs given...

icons/content-types/video webinar

Presenters: Iain MacGilp, Ph.D., Director, GMP Production, Curia Amber McFarlane, Head of Formulation Development, Curia Listen in as our experts discuss: The importance of an integrated formulation development and clinical supply function th...

icons/content-types/article article

As part of our deep commitment to diversity and inclusion in the workplace, Curia (formerly AMRI) is very proud to be participating in the two-year Mansfield Rule: Legal Department Edition (MRLD) initiative.

icons/content-types/article article

CDMOs that routinely handle highly potent compounds must raise the bar for containment, safety, and industrial hygiene. Diverse capabilities across chemistries, purification technologies, and analytical techniques — combined with the ability to sup...

icons/content-types/article article

It is no coincidence that the booms in prefilled syringes (PFS) and biologic medicines are happening at the same time – the two are intrinsically linked. Innovative biologic medicines demand innovative delivery systems to match, and as the utility...

icons/content-types/article article

The pre-filled syringe (PFS) space is one of the fastest growing pharma sectors, expected to be worth $9.7bn by 2025, or 9% CAGR. Compared with traditional vial delivery systems, PFS offers greater patient safety and lower manufacturing costs – bu...

icons/content-types/article article

Syringes have been a mainstay of drug delivery for decades – but, as with many other aspects of healthcare, they have recently undergone something of a revolution. The growth of biological medications, the ever-increasing focus on safety, and a...

icons/utility/left caret 1 2 icons/utility/right caret